To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

NCT00913549 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
DRUG: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)

Sponsor

Sandoz